-
interferon beta-1A
- Avonex (IM once weekly)
- Rebif (SC TIW)
- Plegridy (pegylated - SC Q14 days)
-
glatiramer
- Copaxone
- Glatopa
- MOA: MBP decoy
-
mitoxantrone
- Novantrone
- MOA: Cytocidal and DNA-reactive
-
natalizumab
- Tysabri
- MOA: monoclonal antibody alpha4beta1 cell adhesion
-
alemtuzumab
- Lemtrada
- MOA: humanized cytolytic monoclonal IgG1 antibody
-
fingolimod
- Gilenya
- MOA: agonist of sphingosine 1-phosphate - sequester lymphocytes
-
teriflunomide
- Aubagio
- MOA: limit expansion of t/b cells and decrease migration of lymphocyte into CNS
-
dimethyl fumerate
- Tecfidera
- MOA: mostly unclear - covalently modify cysteine residues
-
cladribine
- MavencladÂ
- MOA: impair DNA synthesis for B/T lymphocytes, cytotoxic
-
ocrelizumab
- Ocrevus
- MOA: C20 on B lymphocyte cytolysis
-
|
|
